This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): transdermal estradiol and norethindrone acetate, estalis
Description: Binding of estradiol to estrogen receptors initiates translocation to the nucleus and and changes in gene expression via estrogen response elements.
Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
Novartis, Noven and Aventis
Through their combined entity Novogyne Pharmaceuticals, Novartis and Noven together bought Combipatch from Aventis Pharmaceuticals. The purchase price consists of a $25 million up-front payment, followed by four quarterly installments of $10 million, payable beginning in the second quarter of 2001. As part of the transaction, Noven received $3.5 million from Aventis, which amount will be reported as revenue over ten years beginning in the first quarter of 2001.
Novartis Pharma AG also acquired the development and marketing rights to future generations of the combination hormone replacement patch in all markets other than Japan, and Novogyne expects to sublicense the U.S. rights to these product improvements. Noven will manufacture CombiPatch and any future combination HRT products, and will supply the products to Novogyne and to Novartis.
Hisamitsu and Noven
In July 2009, Noven Pharmaceuticals and Hisamitsu Pharmaceutical jointly...See full deal structure in Biomedtracker
Partners: Hisamitsu Pharmaceutical Co., Inc.
Pink Sheet Novogyne Combipatch
Pink Sheet Exubera professional ads
Additional information available to subscribers only: